Thank you for your continued interest in Wegovy®. When we introduced this medicine in 2021, we saw significant interest from the healthcare community and patients, resulting in unprecedented product demand. Shortly thereafter, we experienced issues at the contract manufacturing site for Wegovy®, which resulted in supply shortages.  

From the outset, our top priority has been to support current patients who have started treatment with Wegovy® to be able to advance through the dose escalation process and stay on therapy.  We took several steps as part of that commitment. We asked healthcare providers to not start new patients on Wegovy®, we have not advertised or promoted it and more recently, we made the decision to temporarily stop shipments of the first two dose strengths (0.25 mg and 0.5 mg) — all to minimize demand from new patients and increase the likelihood there would be enough product available in the market to meet the needs of current Wegovy® patients.  

Outages of the Wegovy® 1 mg dose strength

Despite these efforts, new prescriptions for Wegovy® continued to occur, resulting in product outages of the 1 mg dose. There will be minimal to no supply of the 1 mg dose strength beginning as early as May, and this will continue into the second half of 2022 when we expect to stabilize supply.

Currently, we are producing limited amounts of Wegovy® 1.7 and 2.4 mg dose strengths. We believe we can meet the needs of patients who are already taking or about to start the 1.7 or 2.4 mg dose strengths and remain confident in our ability to supply them, unless there are significant, unforeseen increases in prescriptions.

We sincerely regret this situation and apologize for any delay or disruption in treatment it may cause. If you have concerns, please contact your healthcare provider to determine the best approach for your treatment plan, in consideration of this supply situation.

Our efforts to restore supply

  • We’re still working toward our commitment to fully restore supply across all doses in the second half of 2022. At this time, we cannot be more definitive with a specific date because several steps are required to fully restore manufacturing capacity, which will have implications for the timeline
  • We expect the contract manufacturer to ramp-up commercial production of Wegovy® over the coming months and we will work on building inventory to meet market demand. Novo Nordisk is also making plans for additional production capacity to come online in 2023
  • We will ensure that we have all dose strengths of Wegovy® within our inventory before we support new patients being initiated and before we start other promotional efforts, consistent with our commitment to continuity of care
  • We will continue to monitor the situation closely and will share timely and transparent updates and keep you informed on our progress

For patients currently taking Wegovy® please know that some pharmacies may continue to experience normal Wegovy® product delays from time-to-time given supply variabilityWe encourage patients to contact their local pharmacy in advance to confirm that the pharmacy will be able to fill your prescription.

We take our commitment to patients and the healthcare community very seriously and are doing everything we can to stabilize Wegovy® supply as quickly as possible. We believe the continued strong demand reflects the significant unmet medical need and the importance of this treatment option.

We appreciate your patience and understand your frustration. If you have concerns, we encourage you to speak to your healthcare provider about the weight management approach that is best for you. 

We are here to help and are ready to answer your questions at 1-833-4-WEGOVY (1-833-493-4689) from 9 AM to 6 PM Eastern Monday through Friday – and select option 0 for more support.

Please see below for important information, and don’t hesitate to call 1-833-4-WEGOVY (1-833-493-4689) and select option 0 for more support. You are our number one priority and we’re here to help.

Please click here for the Prescribing Information and Medication Guide.

Depending on the Wegovy® dose strength you are taking now or may need in the coming weeks and months, this means it is possible you may experience disruption in your treatment, which is an important consideration to discuss with your healthcare provider. Specifically, if you have recently started therapy on the 0.25 mg dose strength, are currently on the 0.5 mg dose strength — and for some patients on the 1 mg dose strength — we do expect there will be a disruption in your treatment.  

Currently, we do have adequate stock of the 1.7 and 2.4 mg doses to meet the needs of patients who are already taking or about to start on these two dose strengths, unless there are significant, unforeseen increases in prescriptions. However, some pharmacies may continue to experience normal delays from time-to-time, so we encourage you to contact your local pharmacy in advance to confirm that they will be able to fill your prescription. It is important to note that any decisions around individualized care should always be made together with a healthcare provider.

We sincerely regret and apologize for any delays and disruptions to your care and encourage you to speak to your healthcare provider about your individual situation and alternative options if you have any concerns.     

We continue to work toward our commitment to fully restore supply across all doses in the second half of 2022. At this time, we cannot be more definitive with a specific date because several steps are required to fully restore manufacturing capacity, which will have implications for the timeline. In the coming months we are working to build inventory and plan to have all dose strengths of Wegovy® available before we support new patients starting treatment and other promotional efforts. We suggest you work with your healthcare provider to determine the best approach for your treatment plan in consideration of this supply situation. Alternative FDA-approved medications for chronic weight management are available.

We've been working hard to restore supply and are making progress. This includes working closely with our contract manufacturer to get production up and running again. We have also increased production at another facility and are making plans for additional production capacity to come online in 2023.

The demand for Wegovy® reinforces the unmet need and has strengthened our promise to not only develop innovative medicines but to partner and advocate to change how obesity is understood, diagnosed and treated.

There are five dose strengths of Wegovy® – the first four increase in a stepwise manner (starting with 0.25 mg, then 0.5 mg, 1.0 mg and 1.7 mg) until the fifth, maintenance dose (2.4 mg). In March, we temporarily stopped shipments of the first two Wegovy® dose strengths (0.25 mg and 0.5 mg). There will be minimal to no supply of the third, 1 mg dose strength, with product outages as early as May that will continue into the second half of 2022 when we expect to stabilize supply. 

Currently, we are producing limited amounts of Wegovy® 1.7 and 2.4 mg dose strengths. We believe we can meet the needs of patients who are already taking or about to start the 1.7 or 2.4 mg dose strengths and remain confident in our ability to supply them, unless there are significant, unforeseen increases in prescriptions.

For more information about the Wegovy® dosing schedule, click here for the Prescribing Information and Medication Guide.

The recent supply issue only affects Wegovy®. Supply of Saxenda® (liraglutide) injection 3 mg, another weight management prescription medicine made by Novo Nordisk, will not be impacted. Please speak with your healthcare provider to discuss your treatment options. Thank you for your continued patience as we work to overcome this temporary setback.

No. There is nothing to indicate there is a product safety issue. 

Although Wegovy ® and Ozempic® both contain semaglutide, they are different products with different indications, dosages, titration schedules, etc. The products are not interchangeable. Alternative FDA-approved medications for chronic weight management are available. We advise you to speak with your healthcare provider to discuss your treatment options. 

We are aware that there are companies purporting to have availability of Wegovy® or semaglutide. We want consumers and healthcare providers to know and be very clear that Novo Nordisk does not sell Wegovy® (or its active ingredient, semaglutide) for the purposes of compounding with other products. We have not conducted studies to evaluate the safety and efficacy of Wegovy® when compounded with other ingredients. Novo Nordisk is the only company that has FDA approval to market Wegovy® and we supply it in a disposable single-use pen available by prescription only.

We also want to acknowledge the growing trend of weight management telehealth providers, many of whom are advertising Wegovy®. Novo Nordisk does not have a relationship with any of these telehealth providers and is not directly supplying Wegovy® to them.

No, the way in which we sell and distribute our products has not changed. We distribute our products to wholesalers who supply retail pharmacies nationwide. Which pharmacies or retailers get Wegovy® is outside of our control.

We do want to note that some pharmacies may continue to experience delays from time-to-time, so we encourage you to contact your local pharmacy in advance to confirm that they will be able to fill your prescription.

Yes, if you have been prescribed Wegovy® and you have commercial insurance, and activated your introductory offer prior to December 31, 2021, the offer will continue to be honored for up to six (6), 28-day fills (1 box) of Wegovy® prior to June 30, 2022. After the sixth fill, or June 30, 2022, you will automatically be enrolled in the current Wegovy® Savings Card offer. Many individuals with coverage for Wegovy® can pay as little as $25 each month. Those without coverage can save up to $500 per 28-day supply of this medicine but should expect an out-of-pocket cost of $800 or more. Please refer to the Terms & Conditions of your savings card for more information.

Please call 1-833-4-WEGOVY (1-833-493-4689) and select option 0.

Let us know! Please rate your experience with this page. *

{{crossValidationError['Was this page helpful'].crossValidationErrorMessage}}

If you have additional comments or would like to provide feedback on what other information would be helpful to you, please contact our Customer Care Center at 1-800-727-6500 or submit online. We will be reviewing that information on an ongoing basis and making periodic updates to this page. Please know that we take our responsibility to support you in this journey very seriously and are addressing this issue as a top priority. Thank you for your patience as we work to resolve this issue – which we will.

Your Career Guide